Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The leukotriene signaling pathway: a druggable target in Alzheimer’s disease
Johanna Michael, Julia Marschallinger, Ludwig Aigner
Drug Discovery Today (2018) Vol. 24, Iss. 2, pp. 505-516
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Identification of early neurodegenerative pathways in progressive multiple sclerosis
Max Kaufmann, Anna-Lena Schaupp, Rosa Sun, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 7, pp. 944-955
Open Access | Times Cited: 97
Transcriptomic Profiling Identifies CD8+ T Cells in the Brain of Aged and Alzheimer’s Disease Transgenic Mice as Tissue-Resident Memory T Cells
Barbara Altendorfer, Michael S. Unger, Rodolphe Poupardin, et al.
The Journal of Immunology (2022) Vol. 209, Iss. 7, pp. 1272-1285
Open Access | Times Cited: 50
A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease: beneficial or detrimental effects
Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 2, pp. 673-688
Closed Access | Times Cited: 27
The journey of boswellic acids from synthesis to pharmacological activities
Ehab A. Ragab, Mohammed F. Abd El-Wahab, Ahmed S. Doghish, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 397, Iss. 3, pp. 1477-1504
Open Access | Times Cited: 22
Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning
Yoichi Morofuji, Shinsuke Nakagawa
Current Pharmaceutical Design (2020) Vol. 26, Iss. 13, pp. 1466-1485
Open Access | Times Cited: 61
Leukotrienes in Tumor-Associated Inflammation
Wen Tian, Xinguo Jiang, Dong-Eon Kim, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 57
Role of antioxidants and a nutrient rich diet in Alzheimer's disease
Gerald Veurink, George Perry, Sandeep Kumar Singh
Open Biology (2020) Vol. 10, Iss. 6
Open Access | Times Cited: 55
5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer’s disease
Fang Chen, Arijit Ghosh, Jingran Lin, et al.
Brain Behavior and Immunity (2020) Vol. 88, pp. 844-855
Closed Access | Times Cited: 54
Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development
Kabir Ahluwalia, Brandon Ebright, Kingsley Chow, et al.
Metabolites (2022) Vol. 12, Iss. 4, pp. 333-333
Open Access | Times Cited: 28
Effects of anti-inflammatory and adaptogenic herbal extracts on gene expression of eicosanoids signaling pathways in isolated brain cells
Alexander Panossian, Ean‐Jeong Seo, Thomas Efferth
Phytomedicine (2019) Vol. 60, pp. 152881-152881
Open Access | Times Cited: 47
Mechanistic role of boswellic acids in Alzheimer’s disease: Emphasis on anti-inflammatory properties
Aisha Siddiqui, Zahoor Ahmad, Rao Nargis Jahan, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 144, pp. 112250-112250
Open Access | Times Cited: 37
Eicosanoid signaling in neuroinflammation associated with Alzheimer's disease
Koppada Lohitaksha, Deepika Kumari, Manas Shukla, et al.
European Journal of Pharmacology (2024) Vol. 976, pp. 176694-176694
Closed Access | Times Cited: 5
Computational Drug Repurposing for Alzheimer’s Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies
Yun Xu, Jiming Kong, Pingzhao Hu
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 31
Arachidonic Acid Derivatives and Neuroinflammation
Era Gorica, Vincenzo Calderone
CNS & Neurological Disorders - Drug Targets (2021) Vol. 21, Iss. 2, pp. 118-129
Closed Access | Times Cited: 30
The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice
Johanna Michael, Julia Zirknitzer, Michael S. Unger, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2782-2782
Open Access | Times Cited: 28
Inhibition of Rho Kinase by Fasudil Ameliorates Cognition Impairment in APP/PS1 Transgenic Mice via Modulation of Gut Microbiota and Metabolites
Yuqing Yan, Ye Gao, Qingli Fang, et al.
Frontiers in Aging Neuroscience (2021) Vol. 13
Open Access | Times Cited: 28
Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline
Ajay Kumar Nair, Carol A. Van Hulle, Barbara B. Bendlin, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 20
Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing
Cátia F. Marques, M. Matilde Marques, Gonçalo C. Justino
Pharmaceuticals (2022) Vol. 15, Iss. 9, pp. 1039-1039
Open Access | Times Cited: 19
Computational screening of potential anti-inflammatory leads from Jeevaneeya Rasayana plants targeting COX-2 and 5- LOX by molecular docking and dynamic simulation approaches
Kadabagere Narayanaswamy Hemavathi, Sinosh Skariyachan, Rajesh Raju, et al.
Computers in Biology and Medicine (2024) Vol. 171, pp. 108164-108164
Closed Access | Times Cited: 4
Adaptogens in Long-Lasting Brain Fatigue: An Insight from Systems Biology and Network Pharmacology
Alexander Panossian, Terrence Lemerond, Thomas Efferth
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 261-261
Open Access
Microglia depletion diminishes key elements of the leukotriene pathway in the brain of Alzheimer’s Disease mice
J. Michael, Michael S. Unger, Rodolphe Poupardin, et al.
Acta Neuropathologica Communications (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 32
A Review of Oxylipins in Alzheimer’s Disease and Related Dementias (ADRD): Potential Therapeutic Targets for the Modulation of Vascular Tone and Inflammation
Lynne Shinto, Jacob Raber, Anusha Mishra, et al.
Metabolites (2022) Vol. 12, Iss. 9, pp. 826-826
Open Access | Times Cited: 16
The Neurodegenerative Hypothesis of Depression and the Influence of Antidepressant Medications
Susan Hall, Brie-Anne Parr, Sarah Hussey, et al.
European Journal of Pharmacology (2024) Vol. 983, pp. 176967-176967
Open Access | Times Cited: 3
The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies
Julia Marschallinger, Barbara Altendorfer, Edward Rockenstein, et al.
Neurotherapeutics (2020) Vol. 17, Iss. 3, pp. 1061-1074
Open Access | Times Cited: 27
Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease
Johan Wallin, Per Svenningsson
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5606-5606
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top